-
Mashup Score: 0
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0How I treat adult T-cell leukemia/lymphoma - 3 month(s) ago
Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive T-cell malignancy that arises in a proportion of individuals who are long-term carriers of…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Thread by @rajshekharucms on Thread Reader App - 4 month(s) ago
@rajshekharucms: Imp. paper by @VincentRK 𝑒𝑡 𝑎𝑙 on mode of progression in a 𝐦𝐨𝐝𝐞𝐫𝐧 𝐜𝐨𝐡𝐨𝐫𝐭 of patients with smoldering #myeloma! Helpful for initial discussion in patients with 𝐇𝐢𝐠𝐡-𝐑𝐢𝐬𝐤 𝐒𝐌𝐌 re. clinical trials vs ac……
Source: threadreaderapp.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Abstract. Acquired mutations in BTK, PLCG2, and BCL2 are associated with resistance to continuous targeted agent therapy in chronic lymphocytic leukemia (CLL). Here, we discuss new evidence that limiting the duration of CLL therapy may prevent the evolution of such resistance mutations, potentially facilitating effective retreatment strategies.See related article by Jain et al., p. 000
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9How I treat refractory and relapsed acute myeloid leukemia - 4 month(s) ago
Using a series of 3 illustrative cases, Thol and colleagues discuss their approach to relapsed/refractory acute myeloid leukemia. Although allogeneic hematopoie
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 52Practical-Haemostasis.com - A Practical Guide and Laboratory Resource for Haemostasis - 5 month(s) ago
Practical-Haemostasis.com is designed to teach you laboratory haemostasis.
Source: practical-haemostasis.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Paper: Ruxolitinib Promotes Clinical Responses in Large Granular Lymphocytic Leukemia Via Suppression of JAK/STAT-Dependent Inflammatory Cascades - 5 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Topics in T Cell, Szary and Hodgkin Lymphomas Hematology Disease Topics & Pathways: Research, clinical trials, Lymphoid Leukemias, adult, Non-Biological therapies, Clinical Research, LGL, Chemotherapy, Diseases, Therapies, Lymphoid Malignancies, Study Population, Human Alison Moskowitz, MD 1, Jahan Rahman 2 *, Nivetha Ganesan 1 *, Kelly Hannigan 2 *, Katie Ksanznak 2 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial - 6 month(s) ago
Addition of gemtuzumab ozogamicin (GO) to induction chemotherapy improves outcomes in older patients with acute myeloid leukemia (AML), but it is unce…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Validate User - 6 month(s) ago
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Validate User - 6 month(s) ago
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission | Journal of Clinical Oncology https://t.co/OEFzVniZXI